Compare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES AUROBINDO PHARMA ALKEM LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x - 14.7 - View Chart
P/BV x 6.4 3.2 199.1% View Chart
Dividend Yield % 0.7 0.4 173.9%  

Financials

 ALKEM LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
AUROBINDO PHARMA
Mar-18
ALKEM LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589809 196.4%   
Low Rs1,232504 244.4%   
Sales per share (Unadj.) Rs417.5281.1 148.5%  
Earnings per share (Unadj.) Rs56.341.4 136.1%  
Cash flow per share (Unadj.) Rs64.750.9 127.2%  
Dividends per share (Unadj.) Rs12.702.50 508.0%  
Dividend yield (eoy) %0.90.4 236.4%  
Book value per share (Unadj.) Rs292.9199.4 146.9%  
Shares outstanding (eoy) m119.57585.88 20.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.3 144.7%   
Avg P/E ratio x25.115.9 157.8%  
P/CF ratio (eoy) x21.812.9 168.9%  
Price / Book Value ratio x4.83.3 146.2%  
Dividend payout %22.66.0 373.2%   
Avg Mkt Cap Rs m168,653384,630 43.8%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m9,17121,308 43.0%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m49,915164,666 30.3%  
Other income Rs m1,6451,020 161.3%   
Total revenues Rs m51,561165,686 31.1%   
Gross profit Rs m8,48237,718 22.5%  
Depreciation Rs m1,0065,580 18.0%   
Interest Rs m671777 86.3%   
Profit before tax Rs m8,45132,380 26.1%   
Minority Interest Rs m-11431 -362.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6068,183 19.6%   
Profit after tax Rs m6,73124,229 27.8%  
Gross profit margin %17.022.9 74.2%  
Effective tax rate %19.025.3 75.2%   
Net profit margin %13.514.7 91.6%  
BALANCE SHEET DATA
Current assets Rs m27,062121,878 22.2%   
Current liabilities Rs m15,32486,806 17.7%   
Net working cap to sales %23.521.3 110.4%  
Current ratio x1.81.4 125.8%  
Inventory Days Days67130 51.2%  
Debtors Days Days4168 60.4%  
Net fixed assets Rs m12,61081,037 15.6%   
Share capital Rs m239586 40.8%   
"Free" reserves Rs m34,490116,218 29.7%   
Net worth Rs m35,027116,804 30.0%   
Long term debt Rs m1,2124,512 26.9%   
Total assets Rs m54,387211,052 25.8%  
Interest coverage x13.642.7 31.9%   
Debt to equity ratio x00 89.5%  
Sales to assets ratio x0.90.8 117.6%   
Return on assets %13.611.8 114.9%  
Return on equity %19.220.7 92.6%  
Return on capital %24.927.4 90.9%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56380,727 8.1%   
Fx outflow Rs m3,01234,700 8.7%   
Net fx Rs m3,55246,027 7.7%   
CASH FLOW
From Operations Rs m7,25919,548 37.1%  
From Investments Rs m1,864-19,570 -9.5%  
From Financial Activity Rs m-9,2738,642 -107.3%  
Net Cashflow Rs m-1508,922 -1.7%  

Share Holding

Indian Promoters % 66.9 54.1 123.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.0 416.4%  
FIIs % 0.0 27.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.2 -  
Shareholders   68,381 69,601 98.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 16, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS